Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Psychiatry/Neurology

Treatment of Duchenne Muscular Dystrophy: Beyond Symptomatic Management

: Internet Activity
: 1.5 AMA PRA Category 1 Credits™
Target Audience
: Physicians, PAs, Nurse practitioners
Expiration Date
: 12/09/2015

Read the content below to launch the activity

Duchenne muscular dystrophy (DMD) is the most frequently occurring and one of the most rapidly progressive childhood neuromuscular disorders. It affects approximately 1 in 3500 live male births throughout the world. Most patients are diagnosed at about age 5 years, when their physical ability diverges markedly from that of their peers. Unfortunately skeletal-muscle involvement in DMD is chronically progressive, resulting in wheelchair-bound patients by age 13 years and being bedbound thereafter. The primary goal of this continuing medical education (CME)-certified activity is to improve patient outcomes in DMD by increasing health care provider (HCP)-understanding and -knowledge of current diagnostic techniques and management strategies, as well as the potential role of genetics and newer treatment interventions.
This educational activity is designed for pediatric or child neurologists in clinical practice.
At the conclusion of this educational initiative, participants will be better able to:
--Discuss the typical clinical presentation of patients with DMD, including common history and physical-examination findings
--Explain current and emerging diagnostic approaches to DMD, laboratory studies, and histologic findings used to confirm the diagnosis, so that treatment can be started earlier
--Describe the general principles of and current guidelines and best practices for the medical management of patients with DMD
--Differentiate among the management needs of children, teens, and young adults with DMD to enable them to make a successful transition to adulthood
--Utilize data and concepts from clinical studies of investigational therapies under development for DMD and integrate different mechanisms of action into treatment strategies
--Review how to counsel patients about selected aspects of genetic, medical, surgical, rehabilitative, and psychosocial management strategies for DMD
Jerry R. Mendell, MD, Chair
Professor of Pediatrics, Neurology, and Pathology
Curran-Peters Chair in Pediatric Research
The Ohio State University College of Medicine
Director of Neuromuscular Disease
Nationwide Children’s Hospital
Columbus, OH
Anne M. Connolly, MD
Professor of Neurology and Pediatrics
Washington University in St. Louis School of Medicine
St. Louis Children’s Hospital
Barnes-Jewish Hospital
St. Louis, MO
Peter B. Kang, MD
Associate Professor of Pediatrics
University of Florida College of Medicine
Chief, Division of Pediatric Neurology
UF Health Shands Children’s Hospital
Gainesville, FL
Perry B. Shieh, MD, PhD
Associate Professor of Neurology
Director, Neuromuscular Program
UCLA Medical Center
Los Angeles, CA
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee for this educational activity.
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient-care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Anne M. Connolly, MD
Grant/Research Support: Eli Lilly and Company; Halo Pharma; Sarepta Therapeutics
Advisory Board: Bristol-Myers Squibb; PTC Therapeutics; Sarepta Therapeutics
Peter B. Kang, MD 
Consultant/Independent Contractor: Sarepta Therapeutics
Grant/Research Support: Pfizer
Jerry R. Mendell, MD
Dr. Mendell does not have any financial disclosures related to this program
Perry B. Shieh, MD, PhD
Speaker’s Bureau: Grifols
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Andrea Funk: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Ashley Marostica, RN, MSN: Nothing to disclose
James Murphy: Nothing to disclose
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.
The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity was released on December 9, 2014 and is valid for one year. Requests for credit must be made no later than December 9, 2015.
In order to receive credit for this activity, the participant must complete the online post-test, with a passing score of 70% or higher, and the online evaluation form.

This activity is jointly provided by Global Education Group and HealthmattersCME.

This activity is supported by an independent educational grant from Sarepta Therapeutics.

Stay Informed

Please click here to register if you would like to be added to our mailing list to receive information on educational materials.

Sign Up Now



Stay Informed

Close this box
required required
Invalid Email required
required required
Submit Close